In 2022, both the EU and the US will continue policy moves to evaluate vulnerabilities in bio/pharma supply chains and recommend solutions to address those vulnerabilities.
By Jim Miller, Content Advisor/Consultant, DCAT. The CDMO sector experienced a strong 2021, but the question for 2022 is whether momentum continues as macroeconomic headwinds create uncertainty.
By Joel Ranck, Market Analyst, BioPlan Associates. What are key trends impacting biomanufacturing for 2022? COVID supply-chain challenges, unpredictable growth capacity, and China are major concerns.
What’s Ahead for the Global Bio/Pharma Market in 2022 & Beyond
Investors and capital markets are playing an increasingly important role in CEOs’ decision-making for their companies’ sustainability goals and actions.
Novartis CEO Targets 20 Key Drugs as Potential Blockbusters
Novartis CEO Vasant Narasimhan is banking on six drugs in the near term and 20 pipeline assets longer term as potential blockbusters. What are the key products?
The EU and Medicines Shortages: Root Causes and Mitigation
The European Commission released a new report detailing medicines shortages in the EU, with manufacturing and quality a leading cause. What’s the solution?
As 2021 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2021? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made.
AstraZeneca is one of seven companies to have its sustainability plan verified under a new science-based Net-Zero Standard for corporate net-zero emissions target-setting. What’s behind the standard?
